Indian Medtech Industry an important driver for the rollout of the scheme
The recently concluded 11th Medtech Conference of Confederation of Indian Industry (CII) brought together industry stalwarts and officials from the government machinery to deliberate on the past achievements and way forward for the medtech industry and its impact on the evolving healthcare scenario in India.
Delivering the keynote address, Suresh Vazirani, Chairman & Managing Director, Transasia Bio-Medicals Ltd. turned the spotlight on the recently launched, ‘Ayushman Bharat Yojna’. Terming this Universal Healthcare Scheme as a historical landmark for mankind, he said, “The Ayushman Bharat scheme is a well-timed recognition for the health of its people. The government and industry need to now join hands to ensure that it is truly beneficial to the targeted 500 mn population.”
In a country where 80% of the medical devices are imported, providing affordable healthcare poses a big challenge. “To ensure healthcare at an annual rate of Rs. 1200 for a family of five, we cannot depend on importing medical devices from developed countries where the average labour cost is Rs. 1200 per hour. That’s the lacuna we need to address,” emphasized Mr. Vazirani.
Sharing his perspective on the way forward, he further stated, “True patient care begins with accurate diagnosis. Currently we need to overcome the roadblocks of quality, affordability and reach. As a country we need to focus on ‘Make in India’ to bridge this gap. Certain policies such as inverted duty structure need to be revisited, in order to ensure the successful implementation of the ‘Make in India’ concept and the Ayushman Bharat scheme at large.”
He cited China as an example of a country that used to rely heavily on imports, but with favourable policies they have now turned the tables; ensuring 80% indigenous manufacturing. “The world has its eyes set on the success of the Ayushman Bharat scheme. And I am positive that if in the next five years, we can Make in India, our medical devices, we will be in a position to drive this scheme to 4 bn people worldwide. That is the power of Make in India,” he added.
“Infact, I am proud that as India’s No. 1 In-vitro Diagnostic Company, Transasia Bio-Medicals Ltd. has been leading the way, manufacturing all its products in India since the 1990s, long before the Make in India concept was formally recognized.” he concluded.
During the panel discussion on ‘Medical Technology Sector – Focus on Manufacturing, Quality, R&D and Innovation’, Mr. Manish Airan, Associate Vice President – Quality, Transasia Bio-Medicals Ltd. cited the need to set up quality product testing processes as well as facilities.“In India, the challenge is maintaining quality of components. If there are no existing local and global regulations; the manufacturers should be able to formulate their own quality standards. At Transasia, we facilitate training and have implemented measures to improve the quality of performance. Structured systems are in place to identify, monitor, and improve supplier systems, thereby ensuring that supplier performance is improved.”
He emphasized that the Bureau of Indian Standards (BIS) should be aligned with global standards. “In the absence of BIS, global standards should be adopted for export competitiveness,” he added.
Thought leaders from across sectors including Mr. Prabal Chakraborty, Vice Chairman & Managing Director, Boston Scientific India; Dr. Naresh Trehan, Chairman, CII Healthcare Council & CMD, Medanta - The Medicity; Mr. Sudhanshu Pandey, Joint Secretary, Ministry of Commerce and Industry and Mr. Himanshu Baid, Managing Director, Poly Medicure Ltd. shared the platform with Mr. Vazirani on putting forth their recommendations to the Government.
About Transasia Bio-Medicals Ltd.:
Founded in 1979, Transasia Bio-Medicals Ltd., India’s Leading In-vitro Diagnostic Company offers products and solutions in Biochemistry, Hematology, Coagulation, ESR, Immunology, Urinalysis, Critical Care, Diabetes Management, Microbiology and Molecular Diagnostics.
Transasia provides doctors and patients with reliable, affordable and innovative Medical Diagnostic Systems, with an impressive install base of above 65,000 equipment across India. It has a vast network of the more than 300+ service and application support specialists, 400+ sales and marketing team, 24 zonal offices and 350+ distributors.
It is the first Indian company to manufacture and export blood analyzers and reagents, in the 1990s. Today, Transasia’s indigenous research has resulted in development of state of the art, ‘Make in India’ products and technologies, enabling its products to be among the best in the world.
All along its journey spanning more than three decades, Transasia has been recognized for its commitment to healthcare. The Govt. of India recently bestowed Transasia with ‘The India Medical Devices Export Company of the Year’ award amongst many others. Besides this, Transasia was conferred the Best Medical Equipment Company of the Year-2017’ by Medgate Today and the ‘Economic Times- Best Healthcare Brand 2016’ amongst many others.
Headquartered in Mumbai, Transasia is a part of the global Erba Diagnostics Mannheim GmbH Group. The Erba –Transasia Group has spread its footprint across USA, UK, Germany, Czech Republic, France, Italy, Russia and Turkey through various acquisitions.
Erba’s production sites in India, Czech Republic and USA and R&D centres in France, UK, India and Czech Republic form a hub for indigenous manufacturing of world class deliverables.Today, the Erba -Transasia Group serves millions across 100 countries. For further information, kindly visit www.erbamannheim.com